GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yichang HEC ChangJiang Pharmaceutical Co Ltd (HKSE:01558) » Definitions » ROC %

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) ROC % : 22.92% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Yichang HEC ChangJiang Pharmaceutical Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Yichang HEC ChangJiang Pharmaceutical Co's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was 22.92%.

As of today (2024-06-09), Yichang HEC ChangJiang Pharmaceutical Co's WACC % is 9.15%. Yichang HEC ChangJiang Pharmaceutical Co's ROC % is 22.22% (calculated using TTM income statement data). Yichang HEC ChangJiang Pharmaceutical Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Yichang HEC ChangJiang Pharmaceutical Co ROC % Historical Data

The historical data trend for Yichang HEC ChangJiang Pharmaceutical Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yichang HEC ChangJiang Pharmaceutical Co ROC % Chart

Yichang HEC ChangJiang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.74 4.59 -4.17 13.89 22.90

Yichang HEC ChangJiang Pharmaceutical Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.48 4.06 16.67 21.34 22.92

Yichang HEC ChangJiang Pharmaceutical Co ROC % Calculation

Yichang HEC ChangJiang Pharmaceutical Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=3147.456 * ( 1 - 12.74% )/( (12593.535 + 11391.393)/ 2 )
=2746.4701056/11992.464
=22.90 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13277.515 - 602.193 - ( 1355.181 - max(0, 5517.443 - 5599.23+1355.181))
=12593.535

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13939.478 - 716.647 - ( 1831.438 - max(0, 4738.491 - 6620.705+1831.438))
=11391.393

Yichang HEC ChangJiang Pharmaceutical Co's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=2917.222 * ( 1 - 3.82% )/( (13089.416 + 11391.393)/ 2 )
=2805.7841196/12240.4045
=22.92 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14705 - 569.805 - ( 4157.161 - max(0, 6188.387 - 7234.166+4157.161))
=13089.416

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13939.478 - 716.647 - ( 1831.438 - max(0, 4738.491 - 6620.705+1831.438))
=11391.393

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yichang HEC ChangJiang Pharmaceutical Co  (HKSE:01558) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Yichang HEC ChangJiang Pharmaceutical Co's WACC % is 9.15%. Yichang HEC ChangJiang Pharmaceutical Co's ROC % is 22.22% (calculated using TTM income statement data). Yichang HEC ChangJiang Pharmaceutical Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Yichang HEC ChangJiang Pharmaceutical Co ROC % Related Terms

Thank you for viewing the detailed overview of Yichang HEC ChangJiang Pharmaceutical Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Business Description

Traded in Other Exchanges
N/A
Address
No. 38 Binjiang Road, Yidu, Hubei Province, Yichang, CHN
Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Olmesartan Tablets, and Clarithromycin Tablets.
Executives
Shao Guan Xin Yu Neng Shi Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Xiang Gang Dong Yang Guang Xiao Shou You Xian Gong Si 2101 Beneficial owner
Shen Zhen Shi Dong Yang Guang Shi Ye Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Guang Dong Dong Yang Guang Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Ru Yuan Yao Zu Zi Zhi Xian Xin Jing Ke Ji Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Ru Yuan Yao Zu Zi Zhi Xian Yu Neng Dian Zi Shi Ye You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Meilan 2201 Interest of corporation controlled by you
Hua Xiaoyi 2201 Interest of corporation controlled by you
Zhang Yushuai 2201 Interest of corporation controlled by you
Blackstone Dawn Pte. Ltd. 2101 Beneficial owner
Blackstone Tactical Opportunities Management Associates (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Inc. 2201 Interest of corporation controlled by you
Btof (dawn Feeder) (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Management Associates Iii (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Lr Associates (cayman) – Nq Ltd. 2201 Interest of corporation controlled by you

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Headlines

No Headlines